Skip to Content
Search Menu

Clinical benefit of nivolumab plus cabozantinib 1st line advanced renal cell carcinoma across subgroups

The CheckMate 9ER study shows an improved PFS across all subgroups. The combination was approved by EMA in March 2021.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Asiaan liittyvä sisältö

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Kidney cancer

Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma

/ Martin Zarba / Jan Andreasen
ASCOGU25Kidney cancer

Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap 

/ Johanne Ahrenfeldt / Jan Andreasen
ASCOGU25Kidney cancer
Sylvie Negrier

Cabozantinib Shows Promising Results in Treatment of Patients with Non-Locally Pretreated Brain Metastases from Renal Cell Carcinoma

/ Sylvie Negrier
ASCOGU25Kidney cancer Play the Video 04:15

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
Bladder cancerESMO24Kidney cancerProstate cancer

Rechallenge of IO/TKI in Second-Line After IO/TKI in First-Line Will Not Add Any Benefits

/ Sofie Pohl
Kidney cancer
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
Bladder cancerESMO24Kidney cancerProstate cancer Play the Video 4:25
Katriina Jalkanen

Belzutifan is Well-Tolerated and Might Be an Addition to a Standard of Care

/ Katriina Jalkanen
ESMO24Kidney cancer Play the Video 04:33
Umang Swami

Single-Agent Cabozantinib is Sufficient and Avoids Extra Toxicity in Metastatic Clear Cell Renal Cell Carcinoma Patients

/ Umang Swami
Kidney cancer Play the Video 06:01
Back to top